Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Vivian Young

Nurse Practitioner Fresno, CA Nurse Practitioner

NPI 1043395528 CMS profile 10610415

6730 N West Ave, Fresno, CA 93711

Open in the dashboard

General payments

$23,793

1,012 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vivian Young of Fresno, CA is reported in the CMS Open Payments database as having received $23,793 across 1,012 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,201 226
2024 General $5,638 221
2023 General $4,177 211
2022 General $4,146 180
2021 General $3,631 174

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vivian Young
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Vivian Young were reported at $6,201. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Vivian Young Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $3,631 $135 $40–$426 $132
2022 $4,146 $152 $48–$470 $149
2023 $4,177 $166 $54–$529 $160
2024 $5,638 $173 $55–$556 $164
2025 $6,201 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $5,071 239 payments
  2. Incyte Corporation $3,242 77 payments
  3. Sun Pharmaceutical Industries Inc. $2,164 78 payments
  4. Janssen Biotech, Inc. $1,999 148 payments
  5. E.R. Squibb & Sons, L.L.C. $1,865 48 payments
  6. Galderma Laboratories, L.P. $1,445 44 payments
  7. Regeneron Healthcare Solutions, Inc. $914 29 payments
  8. Novartis Pharmaceuticals Corporation $886 46 payments
  9. Amgen Inc. $767 36 payments
  10. LEO Pharma Inc. $639 30 payments
  11. Other $4,800 237 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $20,709 997 payments
  2. Consulting Fee $2,042 3 payments
  3. Education $940 11 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $102 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $2,511 105 payments
  2. TREMFYA $2,226 144 payments
  3. OPZELURA $2,195 73 payments
  4. SKYRIZI $1,767 100 payments
  5. SOTYKTU $1,170 43 payments
  6. ILUMYA $1,138 53 payments
  7. HUMIRA $882 44 payments
  8. NEMLUVIO $768 15 payments
  9. Otezla $767 36 payments
  10. DUPIXENT $669 24 payments
  11. Other $9,453 476 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

527

Median for Nurse Practitioner: 389

Drug cost

$184,515

Median for Nurse Practitioner: $21,885

Branded share of claims

11.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 28 $96,370
Otezla Apremilast Brand 14 $69,358
Fluorouracil Generic 86 $6,346
Metronidazole Generic 50 $2,654
Acitretin Generic 11 $1,878
Betamethasone Dipropionate Generic 26 $1,795
Clobetasol Propionate Generic 25 $1,272
Fluocinonide Generic 27 $1,016
Ketoconazole Generic 54 $701
Triamcinolone Acetonide Generic 47 $680

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$864 — —
TREMFYA
$426 — —
SOTYKTU
$409 — —
OPZELURA
$383 — —
SKYRIZI
$369 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

1,012 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record